Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer

被引:13
|
作者
Krüger, W [1 ]
Tögel, F [1 ]
Kröger, N [1 ]
Rössing, S [1 ]
Gieseking, F [1 ]
Gutensohn, K [1 ]
Lindner, C [1 ]
Jänicke, F [1 ]
Zander, AR [1 ]
机构
[1] Univ Hamburg, Hosp Eppendorf, Hamatol Onkol Abt, Bone Marrow Transplantat Ctr, D-20246 Hamburg, Germany
关键词
tumour cells; micrometastases; blood stem cells; high dose therapy; breast cancer;
D O I
10.1007/BF02787354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral blood stem cells were mobilised with G-CSF from steady-state haemopoiesis after previous anthracyclin-containing standard dose chemotherapy in patients with high-risk breast cancer. 48 samples were obtained from patients with stage II-III breast cancer and greater than or equal to 10 lymph nodes, 15 samples from patients with chemotherapy sensitive metastatic disease, and 13 samples from women with inflammatory breast cancer. 44 samples were first or single leukaphereses and 32 samples were second or third harvests. Aliquots were searched for contaminating tumour cells by immunocytochemistry (IC) and cytokeratin-19 reverse transcriptase polymerase chain reaction (rtPCR). The median count of MNCs examined by IC was 2 x 10(6); cDNA prepared from 2 x 10(7) cells was subjected to PCR. Fifty-nine samples were examined by immunocytochemistry, 36 samples by rtPCR, and 19 samples by both techniques. Samples investigated by IC and rtPCR were judged as positive if there was at least one positive test. On the whole, 42/79 (55.3%) of the samples were positive with an insignificant trend to a higher positivity rate in second or subsequent leukaphereses (52.3% vs 59.3%). The median tumour cell load per 10(6) MNCs was low with 0.5 (0-7) cells in all, and a total of 2.2 (0.5-7) cells in positive specimen. Differences in the cancer cell load of first and subsequent leukaphereses and between subgroups of patients were not found. PCR and IC gave consistent results in 63.2%. This phenomenon can be explained by the greater sensitivity of the molecular method and by a Poisson distribution of coharvested tumour cells in samples. Tumour cell contamination in G-CSF mobilised stem cells from patients with breast cancer from steady state haemopoiesis after preceding anthacyclin-containing chemotherapy is frequent, but the tumour cell load is low. To allow a comparison of different studies dealing with cancer cell contamination in stem cells, standardisation of assays is necessary.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [1] Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer
    William Krüger
    Florian Tögel
    Nicolaus Kröger
    Sabine Rössing
    Friederike Gieseking
    K Gutensohn
    Christoph Lindner
    Fritz Jänicke
    Axel R Zander
    Medical Oncology, 1999, 16 : 17 - 22
  • [2] Tumour cell detection in G-CSF mobilised stem cell harvests of patients with high-risk breast cancer
    Krüger, WH
    Tögel, F
    Kröger, N
    Renges, H
    Rauhöft, C
    Lindner, C
    Jänicke, F
    Zander, AR
    BONE MARROW TRANSPLANTATION, 1999, 23 : S147 - S147
  • [3] Effective sequential harvests of G-CSF mobilised peripheral blood stem cells
    Okamoto, Y
    Watanabe, T
    Watanabe, H
    Onishi, T
    Kagami, S
    Kawano, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S218 - S218
  • [4] Peripheral blood stem cell (PBSC) mobilization in breast cancer patients:: Chemotherapy plus G-CSF versus G-CSF alone
    Varo, MJ
    Azaceta, G
    Mayordomo, JI
    Tres, A
    Olave, T
    Moreno, JA
    Domingo, JM
    Gutiérrez, M
    Palomera, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 74 - 74
  • [5] Comparison of two systems for stem cell movilization (G-CSF +/- chemotherapy) in breast cancer patients
    Isla, D
    Herraez, J
    Alonso, M
    Mayordomo, JI
    Cajal, R
    Bueso, P
    Escudero, P
    Moreno, JA
    Palomera, L
    Tres, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 409 - 409
  • [6] A multicenter trial on stem cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus G-CSF or G-CSF alone for mobilization.
    Bertolini, F
    Lanza, A
    Peccatori, F
    Zibera, C
    Gibelli, N
    Perotti, C
    Da Prada, GA
    Pedrazzoli, P
    Torretta, L
    Martinelli, G
    della Cuna, GR
    BONE MARROW TRANSPLANTATION, 1998, 21 : S57 - S57
  • [7] Tumour cell detection in autologous stem cell harvests in patients with high risk neuroblastoma
    Stutterheim, Janine
    Vree, Florentien E. M.
    Zappeij-Kannegieter, Lily
    Caron, Huib N.
    van der Schoot, Ellen C.
    Tytgat, Godelieve A. M.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 432 - 432
  • [8] Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin plus G-CSF in cancer patients
    Joshi, SS
    Miller, K
    Jackson, JD
    Warkentin, P
    Kessinger, A
    CYTOTHERAPY, 2000, 2 (01) : 15 - 24
  • [9] Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma
    Nazha, Aziz
    Cook, Rachel
    Vogl, Dan T.
    Mangan, Patricia A.
    Hummel, Kimberly
    Cunningham, Kathleen
    Luger, Selina
    Porter, David
    Schuster, Stephen J.
    O'Doherty, Una
    Sell, Mary
    Siegel, Don L.
    Stadtmauer, Edward A.
    BLOOD, 2009, 114 (22) : 844 - 844
  • [10] Tumour cells in G-CSF-mobilised stem cells of women with high-risk breast cancer
    Kruger, WH
    Togel, F
    Frerk, O
    Hennings, S
    Kroger, N
    Zander, AR
    BONE MARROW TRANSPLANTATION, 1998, 21 : S62 - S62